Dr. Christopher Lock, M.D./Ph.D.Head of Clinical Trials


• King’s College, University of London
• Westminster Hospital Medical School, University of London, Entrance Scholarship, MD
• Imperial Cancer Research Fund Laboratories, Guy’s and King’s College Hospital,
University of London, PhD
• Internal Medicine / Neurology Jul.1993-Jun.1997 Stanford University Medical Center
• Neuroimmunology Fellow / Clinical Instructor Jul.1997-Jun.2000 Department of Neurology,
Stanford, Supervisor: Dr. Lawrence Steinman, Funding: National Multiple Sclerosis Society

Christopher Lock

Dr. Christopher Lock has dedicated his career to understanding the basic science underlying
Multiple Sclerosis and to caring for patients with Multiple Sclerosis. Over a career of more than
twenty years at Stanford University and the Palo Alto Medical Foundation as a clinician and
basic science researcher, Dr. Lock has published in prestigious journals such as the New England
Journal of Medicine and Nature Medicine, taught medical students, neurology residents and
fellows, worked at a pharmaceutical start-up, and has been an investigator on multiple grants
focused on both treatment and the basic science of Multiple Sclerosis. Visiting Scientist, Roche
Bioscience, Palo Alto, CA, 1997-2000

• Carantech Biosciences, Inc., Mill Valley, CA, 2006-2008 Founder: Dr. Claude Genain. Multiple
sclerosis drug and biomarker development Lead molecule at early preclinical stage of
development. Responsible for planning and conduct of scientific research, development of
expression and purification methods, testing in EAE model.
• Sutter Neuroscience Research Consortium, Peninsula Coastal Lead 2014-2015
• Clinical Associate Professor, Stanford University, Stanford, CA, 2015-Present